GSK plc (LON:GSK) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of GSK plc (LON:GSK) have earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is GBX 1,805.83 ($23.29).

Separately, JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Friday, March 28th.

GSK Trading Down 3.3 %

Shares of GSK opened at GBX 1,417.50 ($18.28) on Friday. The stock has a fifty day moving average price of GBX 1,465.22 and a two-hundred day moving average price of GBX 1,424.23. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The company has a market cap of £57.52 billion, a price-to-earnings ratio of 22.90, a PEG ratio of 1.24 and a beta of 0.31. GSK has a 52-week low of GBX 1,282.50 ($16.54) and a 52-week high of GBX 1,823.50 ($23.51).

GSK (LON:GSK) last released its quarterly earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Analysts predict that GSK will post 175.980975 EPS for the current fiscal year.

Insider Activity

In related news, insider Wendy Becker acquired 536 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The stock was acquired at an average cost of GBX 1,515 ($19.54) per share, with a total value of £8,120.40 ($10,471.18). Also, insider Emma Walmsley sold 38,459 shares of the company’s stock in a transaction dated Monday, February 17th. The shares were sold at an average price of GBX 1,418 ($18.28), for a total value of £545,348.62 ($703,221.95). Insiders own 1.61% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.